Christopher E. Walsh, MD, PhD, is Associate Professor and Director of the Hemophilia Program in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York City. He received his PhD in Biochemistry from Wake Forest School of Medicine and his MD from Tulane University School of Medicine. He then completed an internship and a residency in Internal Medicine at North Carolina Memorial Hospital in Chapel Hill and a residency in Internal Medicine and a fellowship in Hematology at the National Institutes of Health in Bethesda, Maryland. Dr. Walsh is board-certified in Hematology and Internal Medicine.
Dr. Walsh is the Regional Director of ATHN funded HTCs in New England. He sits on the boards of NHF MASAC, American Thrombosis and Hemostasis Network (ATHN), Hemophilia Federation of America and Hemophilia of New York. His basic research focuses on gene therapy of blood diseases. He pioneered the research into Adeno-associated virus and its first use as a gene therapy vector. He is also actively developing gene therapies for hemophilia A and B, von Willebrand disease, and other disorders.
Board Member